CVI-VZV-001

CVI-VZV-001 is an adjuvanted recombinant vaccine developed for the prevention of herpes zoster (shingles). It contains the recombinant varicella-zoster virus glycoprotein E antigen (gE) and a novel liposome-based adjuvant called Lipo-pam, which includes two Toll-like receptor (TLR) agonists. The vaccine is designed to enhance both cellular and humoral immune responses, particularly in older adults, by inducing robust gE-specific T-cell and antibody responses. Preclinical studies demonstrated sustained immunogenicity for up to six months post-immunization and confirmed safety in GLP toxicity tests. The primary indication is the prevention of herpes zoster and reduction of postherpetic neuralgia. As of early 2024, it is undergoing phase I clinical trials in healthy adults aged 50 years and above[1][2][3][4][5][6].

Other names

VZV VaccineHerpes zoster (VZV) vaccineshingles vaccinerecombinant herpes zoster vaccine